Table 2

Effect of PPAR agonist treatment on in vivo parameters and liver weight in WT versus PPARα-null mice

TreatmentGlucoseTriglycerideFFALiver Weight
mg/dl mmol/l % body weight (% change)
WT mice
 Vehicle131  ± 778.5  ± 120.60  ± 0.063.65  ± 0.16
 WY14643, 50 mg/kg/day117  ± 1133.4  ± 92-150 0.49  ± 0.035.86  ± 0.232-160 (60.5)
 TZD, 500 mg/kg/day126  ± 1026.7  ± 52-160 0.08  ± 0.022-160 4.94  ± 0.192-160 (35.2)
 L-783,483, 500 mg/kg/day111  ± 1718.9  ± 32-160 0.18  ± 0.152-150 6.04  ± 0.322-160 (65.5)
PPARα-null mice
 Vehicle123  ± 695.7  ± 210.71  ± 0.064.39  ± 0.39
 WY14643, 50 mg/kg/day129  ± 874.1  ± 70.68  ± 0.134.13  ± 0.22 (−6)
 TZD, 500 mg/kg/day125  ± 777.0  ± 50.37  ± 0.032-160 5.66  ± 0.152-150 (28.8)
 L-783,483, 500 mg/kg/day98  ± 1073.3  ± 190.25  ± 0.092-160 6.97  ± 0.972-150 (58.6)

Mice were treated as indicated for 6 days. All parameters are expressed as mean values (±S.E.).

    • ↵2-150  P < .05;

    • ↵2-160  P ≤ .01. P values were calculated using a t test assuming equal variance.